247 related articles for article (PubMed ID: 34913528)
1. Concomitant variants in NF1, LZTR1 and GNAZ genes probably contribute to the aggressiveness of plexiform neurofibroma and warrant treatment with MEK inhibitor.
Cohen-Barak E; Toledano-Alhadef H; Danial-Farran N; Livneh I; Mwassi B; Hriesh M; Zagairy F; Gafni-Amsalem C; Bashir H; Khayat M; Warrour N; Sher O; Marom D; Postovsky S; Dujovny T; Ziv M; Shalev SA
Exp Dermatol; 2022 May; 31(5):775-780. PubMed ID: 34913528
[TBL] [Abstract][Full Text] [Related]
2. Treatment decisions and the use of MEK inhibitors for children with neurofibromatosis type 1-related plexiform neurofibromas.
Armstrong AE; Belzberg AJ; Crawford JR; Hirbe AC; Wang ZJ
BMC Cancer; 2023 Jun; 23(1):553. PubMed ID: 37328781
[TBL] [Abstract][Full Text] [Related]
3. Combining SOS1 and MEK Inhibitors in a Murine Model of Plexiform Neurofibroma Results in Tumor Shrinkage.
Jackson M; Ahmari N; Wu J; Rizvi TA; Fugate E; Kim MO; Dombi E; Arnhof H; Boehmelt G; Düchs MJ; Long CJ; Maier U; Trapani F; Hofmann MH; Ratner N
J Pharmacol Exp Ther; 2023 May; 385(2):106-116. PubMed ID: 36849412
[TBL] [Abstract][Full Text] [Related]
4. The primacy of NF1 loss as the driver of tumorigenesis in neurofibromatosis type 1-associated plexiform neurofibromas.
Pemov A; Li H; Patidar R; Hansen NF; Sindiri S; Hartley SW; Wei JS; Elkahloun A; Chandrasekharappa SC; ; Boland JF; Bass S; ; Mullikin JC; Khan J; Widemann BC; Wallace MR; Stewart DR
Oncogene; 2017 Jun; 36(22):3168-3177. PubMed ID: 28068329
[TBL] [Abstract][Full Text] [Related]
5. NF1 patient missense variants predict a role for ATM in modifying neurofibroma initiation.
Yu Y; Choi K; Wu J; Andreassen PR; Dexheimer PJ; Keddache M; Brems H; Spinner RJ; Cancelas JA; Martin LJ; Wallace MR; Legius E; Vogel KS; Ratner N
Acta Neuropathol; 2020 Jan; 139(1):157-174. PubMed ID: 31664505
[TBL] [Abstract][Full Text] [Related]
6. Dual mTORC1/2 inhibition induces anti-proliferative effect in NF1-associated plexiform neurofibroma and malignant peripheral nerve sheath tumor cells.
Varin J; Poulain L; Hivelin M; Nusbaum P; Hubas A; Laurendeau I; Lantieri L; Wolkenstein P; Vidaud M; Pasmant E; Chapuis N; Parfait B
Oncotarget; 2016 Jun; 7(24):35753-35767. PubMed ID: 26840085
[TBL] [Abstract][Full Text] [Related]
7. Superimposed Mosaicism in the Form of Extremely Extended Segmental Plexiform Neurofibroma Caused by a Novel Pathogenic Variant in the NF1 Gene.
Veres K; Bene J; Hadzsiev K; Garami M; Pálla S; Happle R; Medvecz M; Szalai ZZ
Int J Mol Sci; 2023 Jul; 24(15):. PubMed ID: 37569527
[TBL] [Abstract][Full Text] [Related]
8. Neurofibromatosis in the Era of Precision Medicine: Development of MEK Inhibitors and Recent Successes with Selumetinib.
Galvin R; Watson AL; Largaespada DA; Ratner N; Osum S; Moertel CL
Curr Oncol Rep; 2021 Mar; 23(4):45. PubMed ID: 33721151
[TBL] [Abstract][Full Text] [Related]
9. A phase 2 study of trametinib for patients with pediatric glioma or plexiform neurofibroma with refractory tumor and activation of the MAPK/ERK pathway: TRAM-01.
Perreault S; Larouche V; Tabori U; Hawkin C; Lippé S; Ellezam B; Décarie JC; Théoret Y; Métras MÉ; Sultan S; Cantin É; Routhier MÈ; Caru M; Legault G; Bouffet É; Lafay-Cousin L; Hukin J; Erker C; Jabado N
BMC Cancer; 2019 Dec; 19(1):1250. PubMed ID: 31881853
[TBL] [Abstract][Full Text] [Related]
10. Mechanisms of loss of heterozygosity in neurofibromatosis type 1-associated plexiform neurofibromas.
Steinmann K; Kluwe L; Friedrich RE; Mautner VF; Cooper DN; Kehrer-Sawatzki H
J Invest Dermatol; 2009 Mar; 129(3):615-21. PubMed ID: 18800150
[TBL] [Abstract][Full Text] [Related]
11. Neurofibromatosis Type 1 and tumorigenesis: molecular mechanisms and therapeutic implications.
Gottfried ON; Viskochil DH; Couldwell WT
Neurosurg Focus; 2010 Jan; 28(1):E8. PubMed ID: 20043723
[TBL] [Abstract][Full Text] [Related]
12. Clonal origin of tumor cells in a plexiform neurofibroma with LOH in NF1 intron 38 and in dermal neurofibromas without LOH of the NF1 gene.
Däschner K; Assum G; Eisenbarth I; Krone W; Hoffmeyer S; Wortmann S; Heymer B; Kehrer-Sawatzki H
Biochem Biophys Res Commun; 1997 May; 234(2):346-50. PubMed ID: 9177273
[TBL] [Abstract][Full Text] [Related]
13. Trametinib Induces Neurofibroma Shrinkage and Enables Surgery.
Vaassen P; Dürr N; Röhrig A; Willing R; Rosenbaum T
Neuropediatrics; 2019 Oct; 50(5):300-303. PubMed ID: 31141829
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of YAP Sensitizes the Selumetinib Treatment for Neurofibromatosis Type 1 Related Plexiform Neurofibroma.
Tian Z; You Y; Xiao M; Liu J; Xu G; Ma C; Du Z; Wang Y
Int J Med Sci; 2023; 20(1):125-135. PubMed ID: 36619222
[No Abstract] [Full Text] [Related]
15. Expanding the clinical phenotype of individuals with a 3-bp in-frame deletion of the NF1 gene (c.2970_2972del): an update of genotype-phenotype correlation.
Koczkowska M; Callens T; Gomes A; Sharp A; Chen Y; Hicks AD; Aylsworth AS; Azizi AA; Basel DG; Bellus G; Bird LM; Blazo MA; Burke LW; Cannon A; Collins F; DeFilippo C; Denayer E; Digilio MC; Dills SK; Dosa L; Greenwood RS; Griffis C; Gupta P; Hachen RK; Hernández-Chico C; Janssens S; Jones KJ; Jordan JT; Kannu P; Korf BR; Lewis AM; Listernick RH; Lonardo F; Mahoney MJ; Ojeda MM; McDonald MT; McDougall C; Mendelsohn N; Miller DT; Mori M; Oostenbrink R; Perreault S; Pierpont ME; Piscopo C; Pond DA; Randolph LM; Rauen KA; Rednam S; Rutledge SL; Saletti V; Schaefer GB; Schorry EK; Scott DA; Shugar A; Siqveland E; Starr LJ; Syed A; Trapane PL; Ullrich NJ; Wakefield EG; Walsh LE; Wangler MF; Zackai E; Claes KBM; Wimmer K; van Minkelen R; De Luca A; Martin Y; Legius E; Messiaen LM
Genet Med; 2019 Apr; 21(4):867-876. PubMed ID: 30190611
[TBL] [Abstract][Full Text] [Related]
16. Genetic disruption of the small GTPase RAC1 prevents plexiform neurofibroma formation in mice with neurofibromatosis type 1.
Mund JA; Park S; Smith AE; He Y; Jiang L; Hawley E; Roberson MJ; Mitchell DK; Abu-Sultanah M; Yuan J; Bessler WK; Sandusky G; Chen S; Zhang C; Rhodes SD; Clapp DW
J Biol Chem; 2020 Jul; 295(29):9948-9958. PubMed ID: 32471868
[TBL] [Abstract][Full Text] [Related]
17. The Use of MEK Inhibitors in Neurofibromatosis Type 1-Associated Tumors and Management of Toxicities.
Klesse LJ; Jordan JT; Radtke HB; Rosser T; Schorry E; Ullrich N; Viskochil D; Knight P; Plotkin SR; Yohay K
Oncologist; 2020 Jul; 25(7):e1109-e1116. PubMed ID: 32272491
[TBL] [Abstract][Full Text] [Related]
18. Pathogenesis of plexiform neurofibroma: tumor-stromal/hematopoietic interactions in tumor progression.
Staser K; Yang FC; Clapp DW
Annu Rev Pathol; 2012; 7():469-95. PubMed ID: 22077553
[TBL] [Abstract][Full Text] [Related]
19. Current status of MEK inhibitors in the treatment of plexiform neurofibromas.
Gross AM; Dombi E; Widemann BC
Childs Nerv Syst; 2020 Oct; 36(10):2443-2452. PubMed ID: 32607696
[TBL] [Abstract][Full Text] [Related]
20. Genetic analyses of mosaic neurofibromatosis type 1 with giant café-au-lait macule, plexiform neurofibroma and multiple melanocytic nevi.
Hida T; Idogawa M; Okura M; Sugita S; Sugawara T; Sasaki Y; Tokino T; Yamashita T; Uhara H
J Dermatol; 2020 Jun; 47(6):658-662. PubMed ID: 32246533
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
